TLR9 Agent Triggers Durable Response in Metastatic Melanoma

Source: Targeted Oncology, December 2019

The use of CMP-001, an intratumoral toll-like receptor 9 (TLR9) agonist, is capable of triggering durable responses when used in combination with pembrolizumab (Keytruda) for patients with PD-1 resistant metastatic melanoma according to results from a phase Ib study presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting (SITC 2019).1

CMP-001 is a CpGA DNA TLR9 antagonist that activates tumor-associated plasmacytoid dendritic cells to produce interferon, which in turn induces antitumor systemic immunity.

“CMP-001 in combination with pembrolizumab was very well tolerated with no apparent increases in autoimmune toxicities associated with anti–PD-1,” explained John Kirkwood, MD, Usher Professor of Medicine and Dermatology at the University of Pittsburgh School of Medicine and codirector of the Melanoma and Skin Care Program at the University of Pittsburgh Cancer Institute and UPMC Hillman Cancer Center.

Menu